Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

ACUTE DANE PARTICLE SUPPRESSION WITH RECOMBINANT LEUKOCYTE-A INTERFERON IN CHRONIC HEPATITIS-B VIRUS-INFECTION JOURNAL OF INFECTIOUS DISEASES Smith, C. I., Weissberg, J., Bernhardt, L., Gregory, P. B., Robinson, W. S., Merigan, T. C. 1983; 148 (5): 907-913

Abstract

The clinical, virologic, biochemical, and immunologic effects of a biosynthetic human leukocyte interferon, recombinant leukocyte A interferon (rIFN-A or HuIFN-alpha 2) are reported in nine patients with chronic hepatitis B virus infection and circulating Dane particle-associated polymerase activity. Eight-day courses of rIFN-A were given starting at a dose of 3 X 10(6) units per day and reaching 68 X 10(6) units per day in two patients. Major toxic side effects included fever, fatigue, gastrointestinal symptoms, myalgias, and headache. Most courses of rIFN-A were associated with a reduction in Dane particle-associated polymerase activity, but in no case was this change permanent. There were also changes in lymphocyte subpopulations at the higher dosage levels of rIFN-A. Because of the reproducible, statistically significant effect on viral replication, further study with this and other biosynthetic interferon species is warranted.

View details for Web of Science ID A1983RR57200018

View details for PubMedID 6631076